Previous 10 | Next 10 |
home / stock / vrtx / vrtx articles
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5...
U.S. stock futures experienced a dip in Monday’s premarket session as investors brace for an earnings-heavy week. Federal Reserve Chair ...
The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, while the index remained in the "Greed" zone on...
Markets are primed for a revival in mergers and acquisitions (M&A) in 2024 following the worst performance in almost a decade for deal-making i...
UBS has downgraded Biogen Inc (NASDAQ:BIIB), noting inflection for its second Alzheimer’s drug Leqembi (lecanemab) will take l...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Tuesday, the FDA approved CRISPR Therapeutics AG’s (NASDAQ:CRSP)/Vertex Pharmaceutical Incorporated’s (NASDAQ:VRTX) Casg...
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) sh...
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual ...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...